cardiogenic shock

Circulatory Support Escalation in Cardiogenic Shock: Outcomes and Predictors of Success

By MedXY 04/28/2026

A multi-center study reveals that circulatory support escalation in cardiogenic shock is associated with higher mortality and complications, but certain patient factors can predict successful outcomes.

Cardiology Critical Care news

Transfer Before Support: Why Cardiogenic Shock Patients Referred from Regional Centers Face Higher Device-Related Complications

By MedXY 04/15/2026

A large observational study reveals that cardiogenic shock patients receiving temporary mechanical circulatory support at regional referral centers before transfer to hub centers experience significantly higher device-related adverse events and mortality compared to those receiving initial support at hub centers, though this difference may be explained by greater illness severity.

Cardiology Critical Care news

Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock

By MedXY 03/10/2026

This clinical analysis of 500 patients identifies heart failure and arrhythmias as the primary causes of SCAI Stage B shock. Key findings highlight acute kidney injury and diuretic resistance as significant predictors of clinical deterioration and the need for escalation of care.

Cardiology Critical Care news

The Warning Signs of Deterioration: Acute Kidney Injury and Diuretic Resistance in SCAI Stage B Cardiogenic Shock

By MedXY 03/01/2026

A large-scale study reveals that 25% of patients with SCAI Stage B cardiogenic shock deteriorate clinically. Acute kidney injury and diuretic resistance are identified as critical, independent predictors of poor outcomes, emphasizing the need for early intervention in 'beginning' shock.

Cardiology Critical Care news

AKI and Diuretic Resistance: Identifying the High-Risk Phenotype in SCAI Stage B Cardiogenic Shock

By MedXY 03/01/2026

New research highlights that nearly a quarter of SCAI Stage B cardiogenic shock patients deteriorate. Acute kidney injury and diuretic resistance serve as critical early warning signs, providing clinicians a window for proactive intervention before hemodynamic collapse.

Cardiology Critical Care news

Plasma Proteomics Unveils VEGFR1 as a High-Precision Prognostic Biomarker in Cardiogenic Shock

By MedXY 01/18/2026

A large-scale proteomic analysis identifies VEGFR1 as a significant, independent predictor of 180-day mortality in patients with cardiogenic shock, offering incremental prognostic value beyond traditional markers like serum lactate and SAPS II scores.

Cardiology Critical Care news

Refining Patient Selection for Microaxial Flow Pumps: The DanGer Shock-like Profile as a Survival Predictor in STEMI-CS

By MedXY 12/31/2025

This study validates the DanGer Shock trial criteria in a real-world registry, demonstrating that patients matching the trial's profile have significantly better survival outcomes when treated with microaxial flow pumps compared to those who do not meet these specific clinical markers.

Cardiology Critical Care news

Beyond Survival: Unpacking the Hemodynamic and Metabolic Benefits of Microaxial Flow Pumps in STEMI-Related Cardiogenic Shock

By MedXY 12/31/2025

Recent substudies from the DanGer Shock trial demonstrate that microaxial flow pumps significantly improve hemodynamics, accelerate lactate clearance, and reduce vasopressor needs in STEMI-related cardiogenic shock, though sex-specific outcomes are heavily influenced by age and treatment delays.

Cardiology Critical Care news

Beyond the DanGer Shock Trial: Real-World Outcomes and Risk Stratification in Impella-Treated Patients

By MedXY 12/31/2025

This article analyzes recent J-PVAD registry data, evaluating the real-world applicability of the DanGer shock trial criteria and prognostic factors for ECPELLA in acute myocardial infarction-related cardiogenic shock, emphasizing the necessity of individualized risk assessment.

Cardiology Critical Care news

Conservative vs Liberal Post‑Oxygenator Targets on VA‑ECMO: Feasibility Concerns and No Early Biomarker Benefit in a Pilot RCT

By MedXY 12/12/2025

A pilot multicenter RCT comparing conservative vs liberal post-oxygenator oxygen targets during VA-ECMO for cardiogenic shock found the conservative approach difficult to maintain (target achieved 33% of time) and no difference in biomarkers of gut, renal, hepatic injury or inflammation.

Cardiology Critical Care news

VA‑ECMO Raises Bleeding and Vascular Complications but Does Not Mediate 30‑Day Mortality in Infarct‑Related Cardiogenic Shock

By MedXY 12/09/2025

A mediation analysis of the randomized ECLS‑SHOCK trial found that VA‑ECMO increased moderate–severe bleeding and vascular complications but these events did not statistically mediate 30‑day mortality in patients with acute myocardial infarction complicated by cardiogenic shock.

Cardiology Critical Care news

Levosimendan Does Not Shorten Time to VA‑ECMO Weaning in Severe Cardiogenic Shock: Results of the LEVOECMO Randomized Trial

By MedXY 12/09/2025

In the LEVOECMO randomized trial (n=205), early levosimendan did not reduce time to successful VA‑ECMO weaning or improve 60‑day mortality versus placebo; ventricular arrhythmias were more frequent with levosimendan.

Cardiology Clinical Updates news

Systolic Blood Pressure as a Key Modifier of Survival Benefit from Microaxial Flow Pump Therapy in Infarct-Related Cardiogenic Shock: Insights from the DanGer Shock Trial

By MedXY 09/27/2025

This post hoc analysis of the DanGer Shock trial reveals that low systolic blood pressure at treatment initiation markedly enhances survival benefit from microaxial flow pump support in infarct-related cardiogenic shock.

Cardiology Critical Care news Specialties

C-Reactive Protein as a Prognostic Biomarker in Infarct-Related Cardiogenic Shock: Insights from the ECLS-SHOCK Trial

By MedXY 08/16/2025

Elevated CRP levels independently predict short-term mortality in acute myocardial infarction complicated by cardiogenic shock, with extracorporeal life support showing no survival benefit regardless of CRP levels or admission timing.